Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
LivaNova (LIVN)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$91.14-3.24%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
4.68 → 4.68 EPS · FY ending Dec 31, 2027 · 7 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 6 to 7; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for LIVN yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Adjusted EPS of $4.20-$4.30 in 2026 | Adjusted EPS is raised to $4.20-$4.30 for 2026. | Intact | Adjusted EPS falls below $4.20 in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 4 of 4 supplied quarters. Management reported: “Adjusted diluted earnings per share for 2026 is now expected to be in the range of $4.40 to $4.50 (versus $4.30 to $4.40 prior), assuming a share count of approximately 56 million for full-year 2026.” “Adjusted diluted earnings per share for 2026 is now expected to be in the range of $4.30 to $4.40 (versus $4.20 to $4.30 prior), assuming a share count of approximately 56 million for full-year 2026.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a growth-oriented medical technology business with recent strong financial performance, but it is still loss-making. The long-term thesis is intact, though its signal has softened from favorable to mildly favorable.
The evidence describes valuation as cheap versus peers, with expectations slightly below the model’s central view and no major fragility flags. That suggests the market is not assuming flawless execution, but valuation evidence has only medium confidence.
Near term, revenue growth and adjusted earnings are tracking management’s raised 2026 guidance, supported by recent quarterly earnings beats. Adjusted free cash flow guidance is lower than the prior year, and a weakening jobs backdrop could add risk; the recent miss probability is described as low.
The multi-year case depends on sustaining revenue growth and delivering the raised adjusted earnings outlook while managing investment needs and cash flow. Near term, a guidance reversal or stronger results from healthcare peers could support the backdrop, while weaker employment data or renewed execution problems could weigh on cyclical healthcare businesses.
LIVN’s long-term thesis remains intact, with operating momentum and peer-relative valuation balanced against ongoing losses and a mixed cash-flow outlook. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Free cash flow of $160-$180 million in 2026 | The company shows solid free cash flow of $160-$180 million. | Intact | Free cash flow falls below $160 million in FY26 | Free cash flow: $35.038M FY2026-Q2; GAAP. Published target: $160-$180 million. Annual target cannot be compared with a quarterly or TTM observation. Aug 5, 202635,038,000 USD · calculatedLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth of 7-8% in 2026 | A primary condition in LivaNova's published investment case. The stated target is 7-8% YoY. | Intact | YoY revenue growth falls below 7% in FY26 | Revenue growth: 9.89% FY2026-Q3; GAAP. Published target: 7-8% YoY. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 20269.893698 percent · calculatedLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 4 of 4 supplied quarters. Management reported: “Financial Summary and Highlights (1) • Third-quarter revenue of $393.1 million increased 9.9% on a reported basis and 10.0% on a constant-currency basis as compared to the prior-year period • Third-quarter U.S. GAAP diluted earnings per share of $0.11 and adjusted diluted earnings per share of $1.23 • Third-quarter net cash provided by operating activities of $73.7 million and adjusted free cash flow of $55.8 million • Raised full-year 2026 revenue growth range by 100 basis points to 9% to 10% on a constant-currency basis.” “2 Full-Year 2026 Guidance LivaNova now expects full-year 2026 revenue to grow between 9% and 10% (versus 8% and 9% prior) on a constant-currency basis.” Revenue was $393.148 million in 2026-Q3. Delivery assessment Nov 5, 2026 |
Maintain valuation discount to peers with PE below 25 | Its valuation is cheap versus peers with a PE of 21.65 versus 36.52. | Intact | PE rises above 25 without earnings growth | P/E (TTM): 23.43x As of 2026-11-05; trailing twelve months. The target timing and basis require a separate assessment. Nov 5, 202623.4293 ratio · calculatedLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$4.63 → $4.68 · observed estimates
$1.62B → $1.63B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $4.63 | $1,617,837,181 | 6 / 8 |
| 2026-07-25 | $4.63 | $1,617,837,181 | 6 / 8 |
| 2026-07-26 | $4.63 | $1,614,403,000 | 9 / 10 |
| 2026-07-27 | $4.63 | $1,614,403,000 | 9 / 10 |
| 2026-07-28 | $4.63 | $1,617,831,837 | 7 / 8 |
| 2026-07-29 | $4.63 | $1,614,403,000 | 9 / 10 |
| 2026-07-30 | $4.63 | $1,614,403,000 | 9 / 10 |
| 2026-07-31 | $4.63 | $1,614,403,000 | 9 / 10 |
| 2026-08-01 | $4.63 | $1,617,831,837 | 7 / 8 |
| 2026-08-02 | $4.63 | $1,614,403,000 | 9 / 10 |
| 2026-08-03 | $4.63 | $1,614,403,000 | 9 / 10 |
| 2026-08-04 | $4.63 | $1,614,403,000 | 9 / 10 |
| 2026-08-05 | $4.63 | $1,614,403,000 | 9 / 10 |
| 2026-08-06 | $4.63 | $1,617,831,837 | 7 / 8 |
| 2026-08-07 | $4.68 | $1,630,534,556 | 7 / 8 |
| 2026-08-08 | $4.68 | $1,627,380,000 | 9 / 10 |
| 2026-08-09 | $4.68 | $1,627,380,000 | 9 / 10 |
| 2026-08-10 | $4.68 | $1,630,534,556 | 7 / 8 |
| 2026-08-12 | $4.68 | $1,627,370,000 | 9 / 10 |
| 2026-08-13 | $4.68 | $1,627,370,000 | 9 / 10 |
| 2026-08-14 | $4.68 | $1,630,534,556 | 7 / 8 |
| 2026-08-15 | $4.68 | $1,630,534,556 | 7 / 8 |
| 2026-08-16 | $4.68 | $1,630,534,556 | 7 / 8 |
| 2026-08-17 | $4.68 | $1,630,534,556 | 7 / 8 |
| 2026-08-18 | $4.68 | $1,630,534,556 | 7 / 8 |
| 2026-08-19 | $4.68 | $1,630,534,556 | 7 / 8 |
| 2026-08-20 | $4.68 | $1,630,534,556 | 7 / 8 |
| 2026-08-21 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-08-22 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-08-23 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-08-24 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-08-25 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-08-26 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-08-27 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-08-28 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-08-29 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-08-30 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-08-31 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-09-01 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-09-02 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-09-03 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-09-04 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-09-05 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-09-06 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-09-07 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-09-08 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-09-09 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-09-10 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-09-11 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-09-12 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-09-13 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-09-14 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-09-15 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-09-16 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-09-17 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-09-18 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-09-19 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-09-20 | $4.68 | $1,633,656,778 | 6 / 8 |
| 2026-09-21 | $4.68 | $1,633,656,778 | 6 / 8 |
| 2026-09-22 | $4.68 | $1,633,656,778 | 6 / 8 |
| 2026-09-23 | $4.68 | $1,633,656,778 | 6 / 8 |
| 2026-09-24 | $4.68 | $1,633,656,778 | 6 / 8 |
| 2026-09-25 | $4.68 | $1,633,656,778 | 6 / 8 |
| 2026-09-26 | $4.68 | $1,633,656,778 | 6 / 8 |
| 2026-09-27 | $4.68 | $1,633,656,778 | 6 / 8 |
| 2026-09-28 | $4.68 | $1,633,656,778 | 6 / 8 |
| 2026-09-29 | $4.68 | $1,633,656,778 | 6 / 8 |
| 2026-09-30 | $4.68 | $1,633,656,778 | 6 / 8 |
| 2026-10-01 | $4.68 | $1,633,656,778 | 6 / 8 |
| 2026-10-02 | $4.68 | $1,633,656,778 | 6 / 8 |
| 2026-10-03 | $4.68 | $1,633,656,778 | 6 / 8 |
| 2026-10-04 | $4.68 | $1,633,656,778 | 6 / 8 |
| 2026-10-05 | $4.68 | $1,633,656,778 | 6 / 8 |
| 2026-10-06 | $4.68 | $1,633,656,778 | 6 / 8 |
| 2026-10-07 | $4.68 | $1,633,656,778 | 6 / 8 |
| 2026-10-08 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-10-09 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-10-10 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-10-11 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-10-12 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-10-13 | $4.68 | $1,633,656,778 | 7 / 8 |
| 2026-10-14 | $4.68 | $1,633,650,878 | 7 / 8 |
| 2026-10-15 | $4.68 | $1,633,650,878 | 7 / 8 |
| 2026-10-16 | $4.68 | $1,633,650,878 | 7 / 8 |
| 2026-10-17 | $4.68 | $1,633,650,878 | 7 / 8 |
| 2026-10-18 | $4.68 | $1,633,650,878 | 7 / 8 |
| 2026-10-19 | $4.68 | $1,633,650,878 | 7 / 8 |
| 2026-10-20 | $4.68 | $1,633,650,878 | 7 / 8 |
| 2026-10-21 | $4.68 | $1,633,650,878 | 7 / 8 |
| 2026-10-22 | $4.68 | $1,633,650,878 | 7 / 8 |
| 2026-10-23 | $4.68 | $1,633,650,878 | 7 / 8 |
| 2026-10-24 | $4.68 | $1,633,650,878 | 7 / 8 |
| 2026-10-25 | $4.68 | $1,633,650,878 | 7 / 8 |
| 2026-10-26 | $4.68 | $1,633,650,878 | 7 / 8 |
| 2026-10-27 | $4.68 | $1,633,650,878 | 7 / 8 |
| 2026-10-28 | $4.68 | $1,633,650,878 | 7 / 8 |
| 2026-10-29 | $4.68 | $1,633,650,878 | 7 / 8 |
| 2026-10-30 | $4.68 | $1,633,650,878 | 7 / 8 |
| 2026-10-31 | $4.68 | $1,633,650,878 | 7 / 8 |
| 2026-11-01 | $4.68 | $1,633,650,878 | 7 / 8 |
| 2026-11-02 | $4.68 | $1,633,650,878 | 7 / 8 |
| 2026-11-03 | $4.68 | $1,633,684,211 | 7 / 8 |
| 2026-11-04 | $4.68 | $1,633,684,211 | 7 / 8 |
| 2026-11-05 | $4.68 | $1,633,684,211 | 7 / 8 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 9 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 2 recorded
1 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.